Publications & Reports

LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.

Pietersz GA, Sandrin MS, Ling S, Li YQ, McKenzie IFC
The Austin Research Institute, Heidelberg, Victoria, Australia.


Drug antibody conjugates can enhance the activity of monoclonal antibodies (MoAb) and idarubicin-MoAb conjugates have led to tolerance induction with antibodies which are inactive when used alone. It has been reported that, in mice, antibodies to ICAM-1 and LFA-1 have to be used together to induce tolerance to cardiac allografts; here we show that these monoclonal antibodies, conjugated to idarubicin, can lead to tolerance induction to cardiac allografts when used alone.


  • Journal: Transplant Immunology
  • Published: 01/10/2001
  • Volume: 9
  • Issue: 1
  • Pagination: 7-11